New drug combo for first-line advanced squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of three medicines (two chemotherapies and an immunotherapy) for people with a certain type of advanced lung cancer called squamous non-small cell lung cancer. The goal is to see if this combo can help shrink or control the cancer better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stage IV squamous non-small cell lung cancer that has spread or come back.
- You have not had any prior treatment for advanced lung cancer, though some past chemotherapy after surgery may be okay if it was more than 6 months ago.
- You are in fairly good health (able to do light activity, ECOG score 0-1).
- Your major organs (like liver, kidneys, blood cells) are working well enough based on blood tests.
- You do not have certain conditions such as active autoimmune disease, uncontrolled infections, or significant bleeding risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (EVM14) combined with an existing immunotherapy called ivonescimab for people with advanced squamous lung cancer that has not been treated before. The goal is to see if the combination is safe and if it helps shrink tumors.
This study tests a new combination of medications to keep stage III lung cancer from coming back after initial radiation and chemotherapy. It aims to see if this approach can help people live longer without their cancer returning.
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This study tests a new combination of two investigational drugs for people with advanced solid tumors, especially lung cancers. The goal is to see if the combination can shrink tumors or slow their growth.
Hear when a new Squamous Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.